Financial Ratios

AUROMED LTD.

NSE : NABSE : 532103ISIN CODE : Industry : Pharmaceuticals & DrugsHouse : Private
BSE0.000 (0 %)
PREV CLOSE ( ) NA
OPEN PRICE ( ) 0.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 0
TODAY'S LOW / HIGH ( )0.00 0.00
52 WK LOW / HIGH ( ) 00
NSE
This Company is not listed in NSE
Select year
ParticularsMar2005Mar2004Mar2003Mar2002
Operational & Financial Ratios
   Earnings Per Share (Rs)0.090.020.010.00
   CEPS(Rs)0.330.070.010.00
   DPS(Rs)0.000.000.000.00
   Book NAV/Share(Rs)9.769.589.379.36
   Tax Rate(%)36.5935.8735.6735.70
Margin Ratios
   Core EBITDA Margin(%)6.61-6.310.720.48
   EBIT Margin(%)4.933.360.700.45
   Pre Tax Margin(%)4.933.320.690.44
   PAT Margin (%)3.122.130.440.29
   Cash Profit Margin (%)11.399.680.460.32
Performance Ratios
   ROA(%)0.900.190.050.03
   ROE(%)0.950.200.060.03
   ROCE(%)1.490.320.090.05
   Asset Turnover(x)0.290.090.110.11
   Sales/Fixed Asset(x)1.551.13158.73147.39
   Working Capital/Sales(x)5.871.443.043.29
Efficiency Ratios
   Fixed Capital/Sales(x)0.640.880.010.01
   Receivable days0.000.000.000.00
   Inventory Days32.32117.54107.94108.91
   Payable days2.1539.2075.0689.12
Valuation Parameters
   PER(x)0.000.000.000.00
   PCE(x)0.000.000.000.00
   Price/Book(x)0.000.000.000.00
   Yield(%)
   EV/Net Sales(x)3.4213.208.599.25
   EV/Core EBITDA(x)25.92120.901200.711919.25
   EV/EBIT(x)69.37392.601234.532070.37
   EV/CE(x)0.980.990.980.98
   M Cap / Sales0.000.000.000.00
Growth Ratio
   Net Sales Growth(%)286.24-2.457.700.00
   Core EBITDA Growth(%)367.221387.7659.940.00
   EBIT Growth(%)467.01371.0767.810.00
   PAT Growth(%)467.20366.5167.830.00
   EPS Growth(%)467.20209.8967.830.00
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.010.00
   Current Ratio(x)6.0412.003.493.02
   Quick Ratio(x)3.276.901.111.04
   Interest Cover(x)585.0675.74148.50155.28
   Total Debt/Mcap(x)

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.